close

Enter

Log in using OpenID

Oncology Drug Pipeline Analysis Market Accrues Phenomenally by 2026 with a Staggering CAGR

embed
The oncology field is witnessing rapid growth, owing to emergence of novel therapies with high efficacy, which in turn is boosting growth of the oncology drug pipeline market. For instance, in 2015, the U.S. Food and Drug Administration (U.S FDA) ap
Oncology Drug Pipeline Analysis Market Necessity
And Demand 2018 to 2026
Oncology Drug Pipeline Analysis Market, by Drug Class (Immunotherapy,
Monoclonal Antibody, Antibody-Drug Conjugate, and Others), by Cancer Type
(Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal
Cancer, Pancreatic Cancer, and Others), by Route of Administration (Oral and
Parenteral), and by Geography - Size, Share, Outlook, and Opportunity Analysis
2018 – 2026
The oncology field is witnessing rapid growth, owing to emergence of novel therapies with high
efficacy, which in turn is boosting growth of the oncology drug pipeline market. For instance, in 2015,
the U.S. Food and Drug Administration (U.S FDA) approved 45 New Molecular Entity (NME) and
new Biologic License Applications (BLA), of which 16 were novel cancer therapies. Therefore,
developments of novel drugs is a major factor propelling growth of the Global Oncology Drug
Pipeline Analysis Market.
Furthermore, increasing initiatives for reducing cancer-related deaths is expected to boost growth of the
market. For instance, in 2017, the World Health Assembly passed a resolution – 'Cancer Prevention and
Control through an Integrated Approach', which urges governments and World Health Organization
(WHO) to accelerate action for minimizing premature mortality in cancer. Such initiatives are expected
to propel growth of the oncology drug pipeline market in the forecast period.
Oncology Drug Pipeline Analysis – Drivers
Innovative approaches in the cancer treatment is a major factor boosting growth of the oncology
pipeline drugs market. For instance, the novel basket study includes patients with a certain genetic
mutation in common, regardless of the site or origin of cancer in the body. Basket studies can be useful
when a drug targets certain genetic mutation at a particular site and using that drug to treat same
genetic mutation in cancer at another site. For instance, Larotrectinib, a drug of Loxo Oncology, Inc., is
currently under review by the U.S. FDA for the treatment of tyrosine kinase mutation by using basket
studies. This drug has been approved as Investigational New Drug in May 2018.
Combinational therapies are the latest development driving the growth of oncology pipeline drugs
market. For instance, Pfizer Inc. is undergoing efficacy and safety study for Avelumab in combination
with chemotherapy, followed by maintenance therapy of Avelumab with PARP inhibitor talazoparib in
patients with history of untreated advanced ovarian cancer. This study is under clinical phase III trials
and is expected to complete in May 2026.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2184
Competitive Landscape
Key players are focused on establishing manufacturing facility in Asia Pacific. For instance, in
September 2018, BeiGene Co.Ltd. —a commercial-stage biotechnology company, selected GE
Healthcare’s bio manufacturing facility— KUBio, for large-scale production of its cancer monoclonal
antibodies in China.
Key players operating in the global oncology pipeline drugs market include, F. Hoffmann-La Roche
Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Pfizer Inc.,
AbbVie Inc., Celgene Corporation, Novartis AG, Merck & Co., Inc., Sanofi, Eli Lilly & Co.,
GlaxoSmithKline, and Amgen Inc.
Oncology Drug Pipeline Analysis – Taxonomy
By Drug Class
•Immunotherapy
•Monoclonal Antibody
•Antibody-Drug Conjugate (ADC)
•Others
By Cancer Type
•Breast Cancer
•Ovarian Cancer
•Prostate Cancer
•Lung Cancer
•Colorectal Cancer
•Pancreatic Cancer
•Others
Oncology Drug Pipeline Analysis – Challenges
Increasing cost of therapies is expected to hinder growth of the oncology drug pipeline market. For
instance, according to a report published in National Center for Biotechnology Information (NCBI),
2016, Pertuzumab-based therapy, used in treatment of HER2 positive breast cancer costs US$ 215,000
per patient.
Moreover, lack of patient’s participation in clinical studies, increase in clinical trial complexity, and
resource constraints are some of the other factors hampering growth of the oncology drug pipeline
market. For instance, according to a report published in Journal of Clinical oncology, June 2012, the
rate of number of cancer patients enrolling in clinical trial worldwide is 3%-5% and the rate has not
improved since 1980.
Oncology Drug Pipeline Analysis – Regional Analysis
On the basis of region, the global oncology drug pipeline analysis market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to
dominate in terms of growth in oncology drug pipeline market. According to the 2015 annual report of
the American Cancer Society, although cancer-related death rate in the U.S. have reduced, cancer still
remains the second most common cause of death in the country. Therefore, such high prevalence of
cancer is expected to drive growth of the oncology drug pipeline market in North America.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran150   documents Email
Document
Category
Health and Medicine
Views
1
File Size
383 KB
Tags
pipeline
1/--pages
Report inappropriate content